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To advance the systems approach in pharmacology, experimental models and computational methods need to be integrated
from early drug discovery onward. Here, we propose outside-in model development, a model identification technique to
understand and predict the dynamics of a system without requiring prior biological and/or pharmacological knowledge. The
advanced data required could be obtained by whole vertebrate, high-throughput, low-resource dose-exposure-effect
experimentation with the zebrafish larva. Combinations of these innovative techniques could improve early drug discovery.
CPT Pharmacometrics Syst. Pharmacol. (2018) 7, 285–287; doi:10.1002/psp4.12297; published online 25 April 2018.
Outside-in model development
Systems biology has developed into a research field elucidat-
ing biological pathways and networks in great detail. These
efforts are not only fueled by the advanced genetic toolbox in
combination with increasingly sensitive and innovative mea-
surement techniques, but especially by combining these
experimental approaches with an “inside-out” modeling strat-
egy.1 Inside-out modeling aims to understand an external
behavior (e.g., cellular apoptosis) by describing the internal
processes (e.g., signal transduction pathways) in as detailed a
way as possible given experimental and mathematical identifi-
ability restraints. The resulting model structures are closely
aligned to the underlying processes, whereas the extensive
amount of experimental data required serves to estimate the
unknown parameters of the model. Similarly, semi mechanistic
pharmacometric and systems pharmacology models adhere
to this modeling paradigm, shifting focus from target-based to
system-based, or phenotypic-based drug development.2,3 In
our current understanding of healthy and diseased organisms
as complex systems, a single drug selective for a single target
within the network would rarely be fully effective.
“Outside-in” model development, on the other hand, is an
approach still mainly used in engineering and there known as
black box system identification. It does not require prior knowl-
edge of the system of interest but allows the precise system
structure and, thus, the dynamics of the system to be
exposed by only observing its response to well-controlled
stimuli (Figure 1a). More specifically, within such identification
approaches, the system of interest is excited with oscillating
stimuli of different frequencies in order to measure the time
resolved response of the system (Figure 1b). For each input
frequency, the amplitude of input and output as well as the
phase shift between input and output are collected and plotted
in a Bode plot (Figure 1c). This visual frequency domain
representation of the dynamics of the system can be trans-
formed into a formula by fitting a so-called transfer function,
which is a representation of a set of linear differential equa-
tions that (in matrix notation) contain the state matrix A, the
input matrix b, the output matrix cT , and the feedthrough
matrix d (for systems with one input and one output is d
scalar). These matrices can then be used to construct the
model structure of the identified mathematical model
(Figure 1d). Thus, the relationship between input and output
of a system can be reconstructed if its complete frequency
response is known.4
One of the advantages of this outside-in approach, the fact
that it does not require prior information on the structure or
the components of the model, makes this analysis method
especially suitable for studying poorly understood (patho)phys-
iological systems, pathways, diseases, or drug effects. Mette-
tal et al.,5 for example, exposed yeast cells to oscillating NaCl
levels of different frequencies and measured a fluorescently
labeled protein as biomarker. Application of the outside-in
approach led them to identify the dominant dynamics in the
osmo-adaptation system in yeast, without considering all
known and unknown reactions. This analysis method, albeit
well-established in engineering, has many advantages still
underappreciated in biology and pharmacology.
In early drug discovery, similarly little may be known about
target pathways or drug effects, making this systems identifica-
tion method of value. Once outside-in modeling uncovers the
system structure and its dynamics, new experiments can be
designed to inform the system model and its detailed compo-
nents, which then allow prediction and interspecies translation
of drug effects. Outside-in modeling is therefore an opportunity
for close collaboration between experimentalist and modeler.
Even though meticulous input/output measurements are still
required, the outside-in approach does not initially require
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exhaustive experimentation typical for inside-out systems biol-
ogy models, thus enabling a fast turnover in testing drug candi-
dates. This method is furthermore not exclusively tailored to
identify model structures from the response of a single target
to a single stimulus; it also extends to multiple drugs affecting
multiple targets or even the whole organism.
Thus, outside-in modeling can initiate the drug discovery
and development learn-and-confirm cycle from the systems
perspective.
High-throughput whole vertebrate experiments in
zebrafish larvae
To use the outside-in methodology in systems pharmacology,
informative data from dedicated input/output experimentation
is needed. As complementary pathways and feedback loops
may attenuate the effect of a single drug compound, pharma-
cological treatment targeting multiple pathways seems more
promising. This means experimental data should reflect per-
turbation of the whole organism as a system, with all intended
and unintended targets available, rather than merely isolated
parts that are taken out of their dynamic physiological context
(Figure 2 right-hand quarters). Additionally, as little time and
resources are available in early drug discovery, performing the
required stimulations at different frequencies is preferably per-
formed in a high-throughput setup (Figure 2 upper quarters).
These types of high-throughput whole organism experiments
are usually performed in invertebrate organisms like yeast
(Saccaromyces cerevisae), round worms (Caenorhabditis
elegans), or fruit flies (Drosophila melanogaster), but are
impractical and unethical for commonly used vertebrate
organisms like rodents. However, high-throughput whole
vertebrate experiments are now possible in a relatively new
model organism; the zebrafish larva (Danio rerio).
The zebrafish is an appealing alternative model organism to
rodents.6 They are easily genetically modified, enabling the
creation of fluorescent reporter lines, as well as disease mod-
els.7 The zebrafish develops quickly, with all major organ sys-
tems like the heart and vasculature, the blood-brain barrier,
liver, gastrointestinal tract, and (pronephric) kidney present
within 72–120 hours after fertilization. This allows for faster
experimentation cycles as compared with traditional verte-
brates like rodents. Moreover, the larvae are transparent, mak-
ing (fluorescence) microscopy highly feasible. Last, their small
size of only a few millimeters in the larval stage, and litter
sizes of 100–200 eggs per breeding couple every 2 weeks,
makes this experimental organism very cost-effective.
Therefore, zebrafish larvae are very suitable for experi-
ments required for outside-in system identification in early
drug discovery and development.
Innovative experimental methods in the zebrafish have been
developed since the turn of the millennium, especially with the
zebrafish larvae. Drug exposure is commonly achieved by
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Figure 1 Outside-in model identification in the frequency domain. (a) Black box model is excited with input u and responds with output
y. (b) Square wave input with amplitude Ain xð Þ (black), output measurements (gray dots), and fitted sinusoid with amplitude Aout xð Þ
and phase shift / xð Þ (gray line) are shown. (c) Bode plot of amplitude ratio and phase shift measurements (red and blue dots, respec-
tively) vs. the frequency of the oscillations (x) are used to fit a transfer function (black lines). (d) The model structure is derived from
the differential equations, which themselves are determined from the transfer function.

















Figure 2 Distribution of current experimental methods and corre-
sponding systems modeling approaches. Models to describe
aspects of a physiological system in general can be developed at
different levels, from subcellular and cellular to tissue-based, organ-
based, and whole organisms. At subcellular and cellular levels,
molecular genetics and biomedical experiments have unraveled
detailed pathways within cells, and cellular environments in tissues
or organs (lower left quarter). Fluorescence labeling, either chemi-
cally or genetically, enables high-throughput screening and sorting
at cellular level (upper left quarter). Moving toward higher hierarchi-
cal levels, organ-on-a-chip informs on organoid processes and inter-
actions (middle). For drug development, the perturbation of the
whole organism system by a drug and quantifying the dynamics of
the perturbation is very relevant, especially when considering multi-
target drugs or combination therapy. Traditionally, from preclinical
rodent and clinical patient data, pharmacometric models are used
to quantify these effects (lower right quarter). Here, we propose the
zebrafish larvae as high-throughput whole vertebrate organism for
outside-in model-informed systems pharmacology, to fill the gap of
high-throughput studies in whole organisms (upper right quarter).
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dissolving the compound of interest in the incubation medium,
allowing for uptake through the skin, the gastrointestinal tract
after it opens at the fourth day postfertilization, and possibly
the gills. Intravenous or intra-yolk administration is, however,
also possible, even in a high-throughput setting. Recently, the
first pharmacokinetic model in zebrafish larvae has been devel-
oped, an important step for this organism toward serving as
model organism for systems pharmacology.8 Additionally,
experimental devices are designed to automatically load and
position larvae in different chambers under the flow of, for
example, drug containing medium. These microfluidic devices
enable precisely controlled dynamic flow of exposure solution
and wash medium, required for the oscillating stimulus of the
outside-in systems identification.9 Integrating such devices with
automated fluorescence microscopy could lead to a closed
experimental setup delivering systems pharmacology data in
an automated high-throughput fashion.10
The availability of these methodologies welcomes experi-
mentalists and modelers to combine forces aimed to tailor
experimental data to a systems pharmacology model,
and vice versa, continuing the learn-and-confirm iterative
approach. Indeed, as the first outside-in data analysis with-
out prior knowledge on the system or target pathways will
result in information on important features of the system
and identify promising candidates, more detailed experi-
ments, and subsequent analyses can be designed and exe-
cuted to elucidate underlying physiological mechanisms.
When a comprehensive understanding of the studied sys-
tem and the perturbing drug candidates has been devel-
oped, this knowledge should advance in the development
pipeline. Knowledge of the system-specific and drug-specific
parameters will then enable reliable interspecies translation
and extrapolation, first from zebrafish larvae to rodent studies,
and finally toward the clinic.
CONCLUSION
Systems pharmacology models inform drug discovery and
development decisions. The models should be fit for purpose,
combining the best of systems biology’s mechanistic under-
standing and pharmacometrics’ quantification of drug pertur-
bations on a system. Although a system can be studied on all
biological levels, from subcellular to whole organism, the latter
is more in line with the current paradigm of pharmaceutical
research. Here, we propose the use of systems pharmacology
in drug discovery and development first by outside-in model
identification, where the prominent factors between drug input
and biological output are modeled without prior knowledge on
the pathways or extensive understanding of the involved pro-
cesses. Indeed, only the relevant rate-limiting elements will be
considered. In early drug discovery, less resources and time
are available, so experimentation should provide enough infor-
mation on these elements within a short time frame. In other
words, high-throughput experiments are preferred, while
retaining information on the drug dose-exposure-response
relationship. Such high-throughput experiments with the possi-
bility of well-controlled oscillating stimuli and noninvasive
detection of response by fluorescence are possible in zebra-
fish larvae contained in a microfluidics device. This precisely
defined input and output data can in turn be used for black
box outside-in model identification, unravelling the most rele-
vant features in a target pathway, and informing on promising
candidates affecting these pathways. Our approach is charac-
terized by close interaction between experimentalists and
modelers, and constant iteration of experiments and computa-
tional analysis, improving each other. When the understanding
of the targets, pathways, and system increases with outside-in
modeling, new experiments and subsequent computational
analyses can be planned. Toward candidate selection, the
understanding of the system-specific and drug-specific proper-
ties of the developed model can be used to extrapolate drug
effects and design rodent studies, continuing the iteration.
This cost-effective and fast approach facilitates the learn-and-
confirm cycle, potentially improving the development of sys-
tems pharmacology models and candidate selection, and
eventually possibly drug discovery and development itself.
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